|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Breast cancer antiestrogen resistance 4 (BCAR4) is a novel long noncoding RNA.
|
30537165 |
2019 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA Breast Cancer Antiestrogen Resistance 4 (BCAR4) has been identified to be oncogenic in several cancers.
|
31173355 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Breast cancer antiestrogen resistance 4 (BCAR4) is a novel long noncoding RNA.
|
30537165 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA Breast Cancer Antiestrogen Resistance 4 (BCAR4) has been identified to be oncogenic in several cancers.
|
31173355 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Overexpression of lncRNA BCAR4 was related to lymph node metastasis (OR 3.68, 95% CI: 2.25-6.00; P < .001), high tumor stage (OR 3.19, 95% CI: 1.98-5.13; P < .001), and distant metastasis (OR 3.83, 95% CI: 2.15-6.82; P < .001), but not to tumor size.
|
31124974 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
The results of analysis showed that BCAR4 expression in human cancer was significantly associated with poor overall survival (hazard ratio [HR] = 1.98, confidence interval [CI]: [1.71-2.29]), p < 0.00001, and high BCAR4 expression was associated with clinical stage (OR and its 95% CI was 3.30 [1.99-5.46], p < 0.00001), distant metastasis (OR = 3.83, 95% CI: 2.15-6.82, p < 0.00001), and lymph node metastasis (OR and its 95% CI was 2.91 [1.62-5.25], p = 0.0004) in patients with cancer.
|
30537165 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
<b>Conclusions</b>: High expression of BCAR4 was correlated with unfavorable overall survival outcome and clinical features including metastasis and progression, implicating an independent prognostic value for BCAR4 in human cancers.
|
31762809 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor xenograft was conducted to determine the effects of BCAR4 and <i>GLI2</i> on NSCLC tumorigenesis in vivo.
|
29615150 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the clinical diagnostic role of BCAR4 in tumors is not completely understood.
|
30537165 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In vivo tumor xenograft study was used to verify the malignancy of CRC cells with inhibition of BCAR4.
|
30962766 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Overexpression of lncRNA BCAR4 was related to lymph node metastasis (OR 3.68, 95% CI: 2.25-6.00; P < .001), high tumor stage (OR 3.19, 95% CI: 1.98-5.13; P < .001), and distant metastasis (OR 3.83, 95% CI: 2.15-6.82; P < .001), but not to tumor size.
|
31124974 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Subgroup stratified analysis showed that tumor type, sample size, follow-up months, and survival analysis method did not alter the predictive value of BCAR4 on OS in various cancers.
|
31762809 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
This meta-analysis indicated the potential value of BCAR4 as a biomarker for predicting a poor prognosis in patients with cancer.
|
30537165 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
In vivo tumor xenograft study was used to verify the malignancy of CRC cells with inhibition of BCAR4.
|
30962766 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Since long non-coding RNA breast cancer anti-estrogen resistance 4 (lncRNA BCAR4) is dysregulated in various types of cancers, we conducted a meta-analysis to determine its prognostic value in cancer.
|
31124974 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
<b>Background</b>: This updated meta-analysis aimed to analyze available data to explore the prognostic value of long noncoding RNA breast cancer anti-estrogen resistance 4 (BCAR4) in various human malignancies.
|
31762809 |
2019 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Long non-coding RNA breast cancer anti-estrogen resistance 4 (BCAR4) has been recognized as a proto-oncogene in various malignancies.
|
31849498 |
2019 |
|
Osteosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Furthermore, the results revealed the prognostic significance of BCAR4 in gastrointestinal malignancy, breast cancer, and osteosarcoma (HR and its 95% CI were 2.05 [1.56-2.68], p < 0.00001; 1.78 [1.46-2.16], p < 0.00001; and 2.47 [1.41-4.34], p < 0.00001, respectively).
|
30537165 |
2019 |
|
Osteosarcoma of bone
|
0.050 |
Biomarker
|
disease |
BEFREE |
Furthermore, the results revealed the prognostic significance of BCAR4 in gastrointestinal malignancy, breast cancer, and osteosarcoma (HR and its 95% CI were 2.05 [1.56-2.68], p < 0.00001; 1.78 [1.46-2.16], p < 0.00001; and 2.47 [1.41-4.34], p < 0.00001, respectively).
|
30537165 |
2019 |
|
Childhood Osteosarcoma
|
0.050 |
Biomarker
|
disease |
BEFREE |
Furthermore, the results revealed the prognostic significance of BCAR4 in gastrointestinal malignancy, breast cancer, and osteosarcoma (HR and its 95% CI were 2.05 [1.56-2.68], p < 0.00001; 1.78 [1.46-2.16], p < 0.00001; and 2.47 [1.41-4.34], p < 0.00001, respectively).
|
30537165 |
2019 |
|
Secondary malignant neoplasm of lymph node
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, elevated BCAR4 level was markedly correlated with advanced clinical stage (III/IV) (OR=3.28, 95% CI: 2.33-4.60), and dramatically predicted lymph node metastasis (OR=3.00, 95% CI: 1.95-4.63, <i>P</i><0.00001) and distant metastasis (OR=3.36, 95% CI: 1.88-5.98, <i>P</i><0.0001), but not associated with age, gender or tumor size.
|
31762809 |
2019 |
|
Secondary malignant neoplasm of lymph node
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
The results of analysis showed that BCAR4 expression in human cancer was significantly associated with poor overall survival (hazard ratio [HR] = 1.98, confidence interval [CI]: [1.71-2.29]), p < 0.00001, and high BCAR4 expression was associated with clinical stage (OR and its 95% CI was 3.30 [1.99-5.46], p < 0.00001), distant metastasis (OR = 3.83, 95% CI: 2.15-6.82, p < 0.00001), and lymph node metastasis (OR and its 95% CI was 2.91 [1.62-5.25], p = 0.0004) in patients with cancer.
|
30537165 |
2019 |
|
Secondary malignant neoplasm of lymph node
|
0.040 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of lncRNA BCAR4 was related to lymph node metastasis (OR 3.68, 95% CI: 2.25-6.00; P < .001), high tumor stage (OR 3.19, 95% CI: 1.98-5.13; P < .001), and distant metastasis (OR 3.83, 95% CI: 2.15-6.82; P < .001), but not to tumor size.
|
31124974 |
2019 |
|
Tumor Cell Invasion
|
0.040 |
Biomarker
|
phenotype |
BEFREE |
Importantly, MMP7 restoration effectively rescued the inhibitory modulations on GBM cell growth and invasion caused by BCAR4 knockdown.
|
31849498 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
The overexpression of BCAR4 promoted NSCLC cell viability, migration, and invasion.
|
29615150 |
2019 |